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Summary
Background: Blocking of lymphocyte trafficking to bile ducts is a potential mecha-
nism to alter the disease course of patients with primary sclerosing cholangitis
(PSC).
Aim: To describe the effect of the a4b7 integrin antibody, vedolizumab, on liver bio-
chemistry and disease activity in patients with PSC and inflammatory bowel disease
(IBD).
Methods: This is a retrospective multi-centre study of adult patients with a diagno-
sis of both IBD and PSC. The primary outcome was change in serum alkaline phos-
phatase level at weeks 14 and 30. Secondary outcomes included changes in other
liver biochemistries and in clinical outcomes for the bowel disease. A safety analysis
for adverse events was performed.
Results: Thirty-four patients (16 Crohn’s disease, 18 ulcerative colitis) were
included. Nine (26%) had a history of liver transplant. Median follow-up on vedolizu-
mab was 9 months (IQR: 7-16). There was no overall change in serum alkaline phos-
phatase level with vedolizumab therapy (median 268 [IQR: 105-551] IU/L at
baseline versus 249 [IQR: 183-634] IU/L, P = 0.99 at week 30). No significant
changes in other liver biochemistries or the Mayo PSC Risk Score were demon-
strated at week 30. Clinical remission was achieved at week 30 in 55% of Crohn’s
disease and 29% of ulcerative colitis patients. Seven (21%) patients ceased vedolizu-
mab; six patients stopped therapy due to persistent IBD activity and one for wors-
ening of liver biochemistries.
Conclusion: Vedolizumab treatment in patients with PSC and IBD did not improve
liver biochemistry but was associated with improvement in bowel disease and a
favourable safety profile.
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1 | INTRODUCTION
Primary sclerosing cholangitis (PSC) causes chronic and progressive
injury to the bile ducts characterised by inflammatory and oblitera-
tive periductal fibrosis, and is the classic hepatobiliary extra-intestinal
manifestation of inflammatory bowel disease (IBD).1 With disease
progression, progressive biliary strictures can lead to cholangitis, bil-
iary cirrhosis and end-stage liver disease.1 Two-thirds of cases of
PSC cases are associated with IBD2 and, although patients are com-
monly asymptomatic at the time of diagnosis, they have a shorter
than average survival compared to matched controls in the general
population.3,4
As PSC is associated with significant morbidity and mortality,
various therapies have been examined in an effort to mitigate the
progressive nature of the disease. Immunosuppressive agents includ-
ing corticosteroids, tacrolimus, ciclosporin, azathioprine, methotrex-
ate and anti-tumour necrosis factor (TNF) therapies have not shown
clinical benefit in PSC.3 Ursodeoxycholic acid, a hydrophilic bile acid
that is often employed to treat cholestatic liver diseases,3,5 has
demonstrated improvement in alkaline phosphatase and other liver
biochemistry in patients with PSC but has not favourably influenced
key endpoints that include death, liver transplantation or progression
to cirrhosis.1,3,6,7
Vedolizumab is a selective humanised monoclonal antibody to
the a4b7 integrin expressed on lymphocytes. The binding of the
a4b7 integrin to MadCAM-1, which is expressed on intestinal
endothelial vessels, allows for gut lymphocyte trafficking.8 Thus
vedolizumab modulates the ability of lymphocytes to enter the gas-
trointestinal epithelium, reducing inflammation and inducing mucosal
healing in patients with moderate-severe Crohn’s disease (CD) and
ulcerative colitis (UC).9-11 Although MAdCAM-1 is not expressed in
normal liver tissue, it is induced in the portal tract endothelium of
inflamed and cirrhotic livers, and its activity correlates with histologi-
cal inflammatory activity in PSC.12,13 It has therefore been postu-
lated that vedolizumab could also be of therapeutic benefit in
patients with PSC. However, experience with vedolizumab in
patients with PSC has been limited to individual-center case ser-
ies.14,15
We studied the use of vedolizumab in a multi-centre, multi-
national cohort of patients with PSC and IBD with a primary focus
on change in liver biochemistry. Secondary outcomes assessed for
changes in prognostic models of PSC and clinical outcomes and
safety of vedolizumab in patients with chronic liver disease and IBD
including patients with orthotopic liver transplant.
2 | MATERIALS AND METHODS
2.1 | Participants
Electronic medical records at participating sites were reviewed for
adult patients with an established diagnosis of concurrent IBD and
PSC (IBD-PSC) based on clinical, biochemical, imaging and endo-
scopic information and who had been initiated on vedolizumab
between June 2014 and January 2016. Data were collected until
August 2016. Participating sites included: University of Chicago
Medicine (n = 11), Medical College of Wisconsin (n = 9), University
of Michigan (n = 7), Northwestern University (n = 4) and Alfred
Hospital, Melbourne, Australia (n = 3). These sites were identified by
a pre-existing collaborative group without prior knowledge to the
number of patients that would meet the inclusion criteria. All
patients that met the inclusion criteria from each site were included
in the study. Institutional review board approval was granted at the
individual participating sites.
2.2 | Study design
A retrospective cohort study was performed. Baseline demographic
information abstracted from the medical record included age, sex,
dates of diagnosis, disease phenotype based on the Montreal classifi-
cation,16 and previous and current use of ursodeoxycholic acid, anti-
inflammatory agents and/or immunosuppressant therapy (steroids,
immunomodulators, anti-TNF agents). Changes to immunomodulator
therapy and UDCA dosing were monitored throughout the study.
Results of orthotopic liver transplant, endoscopic retrograde cholan-
giopancreatography (ERCP), magnetic resonance cholangiopancre-
atography (MRCP) and liver biopsy before and during vedolizumab
treatment were recorded. Clinical scores, laboratory values and
endoscopic outcomes were collected from standard-of-care visits. In
addition, all adverse events including hospitalisations, surgeries, infu-
sion reactions or infections after initiation of vedolizumab were doc-
umented.
2.3 | Outcomes
The primary outcome of interest was a decrease in alkaline phos-
phatase level at weeks 14 and 30 in those with active PSC (patients
with PSC who had not undergone orthotopic liver transplant and
those who underwent orthotopic liver transplant with recurrent PSC
in the transplanted liver). Secondary outcomes of interest included
changes in total bilirubin, Mayo PSC Risk Score,17 alanine amino-
transferase and aspartate aminotransferase at weeks 14 and 30 from
baseline in those with active PSC, and the development of adverse
events at any time. Adverse events were defined as any clinically
significant event that occurred from the date of commencing vedoli-
zumab to the last follow-up. Adverse events were graded as serious
if they resulted in discontinuation of vedolizumab, hospitalisation or
death.
Clinical activity was assessed using the Harvey-Bradshaw Index
(HBI) for CD18 and the Simple Clinical Colitis Activity Index (SCCAI)
for UC.19 In those with clinical disease activity at baseline, rates of
clinical remission and corticosteroid-free remission at week 14 and
30 were determined. Clinical remission was defined as a HBI ≤ 418
or a SCCAI ≤ 2.19 Corticosteroid-free remission was defined as clini-
cal remission without need for concomitant corticosteroids.
In patients with baseline endoscopy and follow-up colonoscopy
after at least 3 months of vedolizumab, endoscopic response was
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assessed utilising the SES-CD for CD patients20 or Mayo endoscopic
subscore for UC.21 In CD, endoscopic improvement was defined as
reduction in the SES-CD > 50% and mucosal healing as SES-CD
score < 3. In UC, endoscopic improvement was defined as absolute
reduction ≥ 1 point in the Mayo endoscopic subscore and mucosal
healing as Mayo endoscopic subscore of 0 or 1. Biopsies in CD and
UC were scored on a 4-point scale as quiescent/normal (0), mild (1),
moderate (2) or severe (3).22 Histological improvement was defined
as an absolute reduction of 1 point or more and histological remis-
sion as score of 0.
2.4 | Statistical methods
Patients were analysed on an intent-to-treat basis and cessation of
vedolizumab for any reason was considered treatment failure.
Descriptive statistics were provided to summarise demographic char-
acteristics using mean (95% confidence interval [CI]) or median (in-
terquartile range [IQR]) for continuous variables, and number and
percentage for categorical variables. As the differences between
liver biochemistry were not normally distributed, the Wilcoxon’s
signed-rank test was used for statistical analysis of response to
treatment. Pre-treatment and post-treatment biochemical indices
and Mayo PSC Risk Scores were compared between week 0 and
week 14 and week 0 and week 30. For patients who withdrew pre-
maturely, the last observation was carried forward. A two-sided P-
value ≤ 0.05 was considered statistically significant. All data analyses
were performed using Stata 12.0 (STATACORP, College Station, TX,
USA).
3 | RESULTS
3.1 | Baseline characteristics
Demographics, baseline characteristics and medication usage of the
34 patients with PSC-IBD who met inclusion criteria are shown in
Table 1. Included patients and clinical outcomes assessed are out-
lined in Figure 1. Of the nine (26%) patients who had undergone
orthotopic liver transplantation for PSC prior to initiation of vedoli-
zumab, 3 had recurrent PSC demonstrated on liver biopsy. Thus, 28
patients (71% large duct) had active PSC at the time of treatment
with vedolizumab.
Vedolizumab was commenced for IBD clinical disease activity in
the majority of patients (n = 27, 79%). Other indications for vedoli-
zumab included possible therapeutic benefit in active PSC (n = 3),
intolerance of previous maintenance medication (n = 1), transition
from natalizumab (n = 1) and severe endoscopic disease activity
despite clinical remission (n = 1). Median clinical follow-up while on
vedolizumab was 9 (IQR: 7-16) months and 28 (82%) patients had at
least 6 months of clinical follow-up.
At commencement of vedolizumab, 7 patients were on long-term
ursodeoxycholic acid, the dose of which did not change in these
patients throughout the study period. Two patients commenced
ursodeoxycholic acid during the study period.
3.2 | Efficacy
3.2.1 | Alkaline phosphatase
Alkaline phosphatase levels from all patients with active PSC and bio-
chemical testing before and after vedolizumab are shown in Table 2
and Figure 2. Overall, there was no significant change in alkaline phos-
phatase levels before and after treatment with vedolizumab at week
14 or 30. Median alkaline phosphatase activities were 268 (IQR: 105-
551) IU/L before treatment, 234 (IQR: 126-396) IU/L, P = 0.346 at
week 14 and 249 (IQR: 183-634) IU/L, P = 0.990 at week 30. The
median percentage change from baseline in alkaline phosphatase was
0% [IQR: 17%, 10%] at week 14 and 1% [IQR: -20%, 21.7%] at
week 30.
Of the 18 patients (69%) with an elevated alkaline phosphatase
at baseline, 11 patients (61%) improved but none achieved a normal
alkaline phosphatase at week 30 (Figure 2A). Alkaline phosphatase
did significantly fall with treatment at week 14 from median 475
(IQR: 241-757) IU/L at baseline to 322.5 (IQR: 220-651) IU/L at
week 14 (P = 0.025). However, two patients potentially confounded
this analysis with a fall associated with the commencement of
ursodeoxycholic acid (where alkaline phosphatase activities fell by
75% and 13%, respectively, as shown in Figure 2A). At week 30,
median alkaline phosphatase activities only trended down to 283
(IQR: 207-658) IU/L (P = 0.267). When patients who were com-
menced on ursodeoxycholic acid during vedolizumab treatment were
excluded, the decrease in alkaline phosphatase only trended to sig-
nificance at week 14 (P = 0.070) and was again not significant at
week 30 (P = 0.866). The median percentage change in alkaline
phosphatase among individuals with an elevated baseline level was
10% [IQR: 38%, 0%] at week 14 and 12% [IQR: 24%, 2%] at
week 30. In most cases, improvement was evident by week 14; only
one patient with transient worsening of their alkaline phosphatase at
week 14 achieved improvement in their alkaline phosphatase at
week 30. No clear demographic or clinical characteristics, including
the duration of PSC, type of PSC (small-duct vs large-duct) and type
of IBD (CD vs UC), defined patients with alkaline phosphatase
improvement (data not shown).
Of the eight patients (31%) with normal alkaline phosphatase at
baseline, four (50%) had a subsequent increase in its activity to abnor-
mal levels over the 30 weeks of treatment (Figure 2B). Overall, in
these eight patients, there was a significant increase in alkaline phos-
phatase from a baseline median of 98 (IQR: 77-102) IU/L to 110 (IQR:
102-183) IU/L, P = 0.019 at week 14 and to 146 (IQR: 90-203) IU/L,
P = 0.036 at week 30. The median percentage change among individ-
uals with a normal baseline alkaline phosphatase was +20% (IQR: 5%,
80%) at week 14 and +48% (IQR: 4%, 94%) at week 30.
3.2.2 | Total bilirubin, aspartate aminotransferase,
alanine aminotransferase and Mayo PSC Risk Score
As shown in Table 2 and Figure 3, there were no significant changes
in the median serum total bilirubin, aspartate aminotransferase or
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alanine aminotransferase over 14 or 30 weeks’ therapy with vedolizu-
mab. The calculated Mayo PSC Risk Score for PSC did improve signifi-
cantly from baseline to week 14 from mean -0.40 [95% CI: 0.85,
0.05] at baseline to -0.59 [95% CI: 0.99, -0.18] at week 14
(P = 0.03). This difference was no longer significant at week 30 with a
Mayo PSC Risk Score of 0.38 [95% CI: 0.83, 0.08] (P = 0.90) (Fig-
ure 3D).
3.3 | Clinical activity of intestinal disease
All 34 patients had clinical assessment of their intestinal disease activ-
ity before and after vedolizumab therapy was initiated and 25 patients
(11 CD; 14 UC) had clinically active IBD (HBI > 4 or SCCAI > 2) at
baseline. Among those with CD, 5 (45%) patients achieved clinical
remission by week 14, increasing to 6 (55%) by week 30. In those with
TABLE 1 Baseline characteristics of patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD)
Characteristic Crohn’s disease, n = 16 Ulcerative colitis, n = 18
All patients: n = 34
Male gender, n (%)
9 (56%) 15 (83%)
Median age IBD diagnosis, y (IQR) 19.5 (17-24) 22 (18-39)
Median age, y (IQR) 34 (25.5-38.5) 37 (23-46)
Median duration of disease, y (IQR) 10.5 (7.5-18.5) 10 (3-15)





Current smoker, n (%) 2 (13%) 0 (0%)
Clinical disease activity at baseline, n (%) HBI
<5 (remission): 5 (31%)
5-7 (mild): 5 (31%)
8-16 (moderate): 6 (38%)
>16 (severe): 0 (0%)
SCCAI
<3 (remission): 4 (22%)
3-6 (mild): 8 (44%)
7-10 (moderate): 4 (22%)
>10 (severe): 2 (11%)
History of liver transplant, n (%) 2 (13%) 7 (39%)
Recurrent PSC in transplanted liver, n (%) 1 (50%) 2 (25%)
Active PSC at vedolizumab commencement, n (%) 15 (94%) 13 (72%)
Anti-TNF treatment na€ıve, n (%) 1 (6%) 6 (33%)
Concomitant medications at commencement, n (%)
Tacrolimus 2 (13%) 7 (39%)
Immunomodulator 6 (38%) 7 (39%)
Glucocorticoids 4 (25%) 8 (44%)
Antibiotics 1 (6%) 1 (6%)
Median prednisolone equivalent dose, mg (IQR) 40 (30-40) 15 (10-40)
Patients with PSC and biochemical testing before and after vedolizumab: n = 26
Median age of PSC diagnosis, y (IQR) 24 (20-29) 22 (20-43)
Median duration of PSC, y (IQR) 8 (3-10) 3 (1-8)
Cirrhosis, n (%) 2 (14%) 0 (0%)
History of biliary stricture dilation, n (%) 5 (36%) 4 (33%)
On UDCA, n (%) 5 (36%) 2 (17%)
Median daily urosodeoxycholic acid dose, mg (IQR) 900 (900-1000) 1000 (1000-1000)
Biochemistry at baseline, median (IQR)
Alkaline phosphatase (IU/L) (normal <120) 268 (99-551) 283 (108-618)
Aspartate aminotransferase (IU/L) (normal <30) 34 (24-98) 81 (50-111)
Alanine aminotransferase (IU/L) (normal <120) 42 (20-144) 86 (27-139)
Albumin (g/dL) (normal 3.9-4.4) 3.5 (2.9-4.5) 4.1 (3.9-4.3)
Total bilirubin (mg/dl) 0.5 (0.4-0.6) 0.8 (0.6-1.6)
Baseline Mayo Risk Score, mean (95% CI) 0.55 (1.38-0.27) 0.26 (0.81-0.29)
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UC, 3 (21%) achieved clinical remission by week 14, increasing to four
(29%) by week 30. Of the 12 patients (4CD; 8UC) who were on corti-
costeroid therapy at baseline, 10 (83%) (3CD; 7UC) were weaned from
corticosteroids during follow-up and 4 (33%) (2CD; 2UC) achieved cor-
ticosteroid-free remission by week 30 (Figure 4A). Eight of 9 (89%)
patients in clinical remission at initiation of therapy remained in clinical
remission through to 30 weeks.
3.4 | Mucosal healing
Thirteen patients (6CD; 7UC) had baseline endoscopic disease activ-
ity and follow-up assessment for mucosal healing at median time of
6 (IQR: 5, 10) months. Of the 6 CD patients, two (33%) achieved
endoscopic improvement, but none achieved mucosal healing. None
of five patients with CD who had histological assessment showed
histological improvement or healing. Of the seven UC patients, two
(29%) achieved endoscopic improvement and one (14%) mucosal
healing. Six of those patients had histological assessment; 3 (50%)
achieved histological improvement and 1 (17%) histological remission
(Figure 4B). There was no association between mucosal improve-
ment and change in serum alkaline phosphatase activity, with 33%
and 29% of those who had deterioration and improvement of their
alkaline phosphatase, respectively, achieving endoscopic improve-
ment with vedolizumab treatment (P = 1.00).
3.5 | Safety and adverse events
Median follow-up was 9 (IQR: 7, 16) months. Seven (21%) patients
ceased vedolizumab after a median of 8 (IQR: 5, 8) months, six for
ongoing clinical disease activity and one for deteriorating LFTs. The
patient with worsening LFTs had normal liver biochemistry at base-
line; the alkaline phosphatase increased to 351 IU/L and alanine
aminotransferase 264 IU/L at week 14. This patient proceeded to
liver biopsy with histological findings consistent with a drug reaction
thought secondary to vedolizumab. Vedolizumab was ceased at
week 16 and the liver biochemistries returned to normal over the
following 3 months. Two further patients had liver-related complica-
tions and were hospitalised for cholangitis, but continued on vedoli-
zumab. Of these, one was found to have a dominant stricture that
was dilated at ERCP, and the other patient proceeded to liver trans-
plantation. One patient was hospitalised for poorly controlled intesti-
nal disease, resulting in colectomy.
TABLE 2 Change in liver biochemistry and Risk Score with vedolizumab
Baseline Wk 14
P-value: difference





268 (105, 551) 265 (176, 508) 0.346 236 (183, 634) 0.990
Bilirubin (IU/L)
median (IQR)
0.6 (0.4, 0.9) 0.7 (0.4, 1) 0.619 0.7 (0.4, 1.3) 0.960
AST (IU/L)
median (IQR)
54 (27, 98) 37 (23, 75) 0.215 46 (39, 93) 0.693
ALT (IU/L)
median (IQR)
63 (20, 144) 50 (31, 107) 0.459 58 (39, 154) 0.809
Mayo PSC Risk Score
Mean (95% CI)
0.40 (0.85-0.05) 0.59 (0.99 to 0.18) 0.030a 0.38 (0.83-0.08) 0.879
aSignifies statistical significant difference.
34 Patients with a
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There were four (12%) minor adverse events that did not require
hospitalisation, change in therapy, or medical intervention. They
included one patient who developed an upper respiratory tract infec-
tion, one with headaches, one dental abscess and one with diarrhoea
associated with Aeromonas on stool culture.
4 | DISCUSSION
Despite multiple studies investigating treatment options for PSC,
currently there is no effective medical therapy. It has been postu-
lated that vedolizumab, a selective a4b7 integrin antibody, may alter
the disease course of progressive PSC by blocking lymphocyte traf-
ficking to bile ducts, which, during chronic inflammation, express
MadCAM-1. However, the findings of the current multi-centre, mul-
ti-national cohort suggest that vedolizumab has little impact on liver
biochemistry or the Mayo PSC Risk Score in the vast majority of
patients with PSC. Some patients did demonstrate a small and per-
sistent decrease in the serum alkaline phosphatase following initia-
tion of vedolizumab, but likewise there were several patients who
commenced the study with normal alkaline phosphatase levels and
also had small subsequent increases in their alkaline phosphatase.
While our findings support a tendency in patients with elevated
alkaline phosphatase and PSC-IBD to decrease the enzymes
concentration early in follow-up, the effect was not sustained
through 30 weeks, nor did it represent a clinically meaningful change
in only 10% difference in alkaline phosphatase following vedolizu-
mab treatment. In addition, four of eight patients with normal alka-
line phosphatase at commencement of therapy developed abnormal
levels over 30 weeks of therapy and the overall increase in alkaline
phosphatase levels in these patients was statistically significant at
both week 14 and week 30. Of note, this increase was not due to
the PSC in all patients and, despite this increase, only one patient
required cessation of vedolizumab secondary to drug-induced liver
damage and not progression of their PSC. However, the overall
changes in alkaline phosphatase, both up and down, were small and
appeared clinical inconsequential. Certainly, the short-term biochemi-
cal effects in this study do not inspire confidence that longer term
results will be any more impressive.
Whether vedolizumab slows the progression of alkaline phos-
phatase increase cannot be ascertained without a control group.
Reduction in alkaline phosphatase has been associated with longer
survival in PSC, and a recent PSC study group consensus statement
identified alkaline phosphatase as a potentially promising surrogate
endpoint for PSC clinical trials.23 However, the potential that
changes in liver biochemical profile do not reflect long-term progres-
sion of liver disease must be taken into account in interpreting the





































































F IGURE 2 Change in Alkaline Phosphatase following treatment with vedolizumab. *Indicates significant decrease (P < 0.05) from wk 0
level. Shaded region represents normal range of alkaline phosphatase (<120 IU/L). The columns indicate the median value for each group. (A)
Patients with elevated alkaline phosphatase ( ≥ 120 IU/L) level at baseline. There was a statistically significant decrease at wk 14 (P = 0.025).
This decrease was no longer statistically significant at wk 30 (P = 0.267). (B) Patients with normal alkaline phosphatase activities at baseline.
There was a significant increase at week 14 (P = 0.02) and 30 (P = 0.04)


























































































































F IGURE 3 Liver biochemistry and Mayo PSC Risk Score before and following 14 and 30 wk’ treatment with vedolizumab in patients with IBD-
PSC. *Indicates significant decrease (P < 0.05) from wk 0 level. Shaded region represents normal range of factor. The columns indicate the median
value for total bilirubin, AST and ALT and mean value for Mayo PSC Risk Score. (A) Total bilirubin: no change in total bilirubin with treatment. (B)
Aspartate aminotransferase (AST) activities; no change with treatment. (C) Alanine aminotransferase (ALT) activities: no change with treatment. (D)
Mayo PSC Risk Scores: improvement in Mayo PSC Risk Score from baseline to week 14 (P = 0.03), but not to wk 30 (P = 0.90)
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the most well described treatment for PSC, indicate that significant
improvement in liver biochemistries in patients with decrease serum
alkaline phosphatase activities by up to 67%6,24-26 have not been
reflected in improved clinical outcomes and in fact, more recently,
high-dose ursodeoxycholic acid has been associated with worsening
clinical outcomes and the development of colorectal cancer.27,28
Whether PSC itself is at all reversible is something that is yet to
be determined. In this short-term study, we have relied on improve-
ment in liver biochemistry to determine the utility of vedolizumab in
patients with PSC. It is therefore presumed that, in part at least, the
damage and increase in alkaline phosphatase in PSC is reversible.
This may not be the case and is a limiting factor in all studies exam-
ining treatment options for PSC. Currently, trials in PSC therapeutics
have been severely hampered by the time taken to reach clinically
significant end-points and that there is no well-defined early surro-
gate marker for disease outcomes.29 This study is no different and
longer term, multi-centre and case-control studies of patients with
PSC and IBD treated with vedolizumab will be required to determine
if exposure to vedolizumab alters the rate of development of
advanced liver disease, need for liver transplant, colorectal cancer
and cholangiocarcinoma despite seeming to have little benefit on
liver biochemistry.
In this study, IBD-PSC patients who had active intestinal disease
achieved rates of clinical remission with vedolizumab similar to those
previously reported.11,30-33 However, despite vedolizumab being clin-
ically effective in the IBD-PSC patient cohort, we found low rates of
mucosal healing and histological remission. It has previously been
reported that vedolizumab achieves mucosal healing in 50% of UC
patients9,31 and 20%-30% of CD patients.11,31 In our study, no
patient with CD and PSC achieved mucosal or histological healing
and only one of seven with UC achieved mucosal healing and histo-
logical remission. How these rates compare directly to IBD-PSC
patients on other therapies is unknown but a recent paper by Kru-
gliak Cleveland et al34 did demonstrate that UC patients with PSC
who were in clinical remission were significantly more likely to have
endoscopic and histological inflammation compared to UC patients
without PSC. This warrants further attention as ongoing histological
inflammatory activity35 and PSC36 are associated with an increased
risk of bowel neoplasia. Furthermore, a theoretical concern with the
use of vedolizumab is an increased risk of colorectal cancer due to
decreased immune surveillance of the gut. Reassuringly, no associ-
ated increased risk of colorectal cancer has been found in long-term
safety studies on vedolizumab compared to the general IBD popula-
tion.37
Our study has shown that vedolizumab is safely administered to
patients with IBD-PSC. In this cohort, seven (21%) patients ceased
vedolizumab therapy after a median of 8 months (IQR: 5.5, 8) of
which six were for primary nonresponse to vedolizumab. One patient
had normal liver function tests prior to commencing vedolizumab
but developed drug-related hepatotoxicity and was required to cease
vedolizumab. Two further patients did develop cholangitis, one of
which required liver transplantation for deterioration of liver disease
and recurrent cholangitis after 7 months of therapy. The second
patient had an elevated liver function profile at baseline that failed
to improve after 3 months of vedolizumab therapy and was found
to have a dominant biliary stricture on ERCP that required dilation.
There were no other severe adverse events associated with vedoli-
zumab use in this population, and the 12% of patients with minor
adverse event were expected and similar as those reported in previ-
ous studies.11,30,31
There are a number of notable limitations to this study. First, all
data collection was performed retrospectively, but, since the
included centres are all major referral centres for IBD and liver dis-
ease, we were able to collect data obtained from routine clinic visits.
Although we strengthened the data quality using objective outcome
assessments where possible, there may still be bias present in the
clinical follow-up of patients. Secondly, the sample size was small,
which may have contributed, for example, to the failure to observe
statistical significance in changes in liver biochemistry, particularly at
























































F IGURE 4 Effects of vedolizumab on disease activity in patients with clinically active disease on initiation of therapy. (A) Proportion of
patients in clinical remission and corticosteroid-free clinical remission. (B) Proportion of patients with endoscopic response or healing following
vedolizumab therapy
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However, the absolute difference in the primary outcomes of alka-
line phosphatase levels does not appear to be clinically significant
even if larger patient numbers were able demonstrates a statistically
significant difference. The small sample size, however, also did not
allow comparison of liver biochemistry improvement between differ-
ent sub-groups including those with intra versus extrahepatic PSC or
history of liver transplant to be adequately explored. The patients
included in this study were also more likely to have CD than UC
which is not reflective of the ratios of CD versus UC in the general
PSC population. This is likely secondary to the fact that at the time
of this study vedolizumab was primarily used to treat the intestinal
disease activity rather than the PSC and in some centres, including
the University of Chicago, the majority of patients commenced on
vedolizumab had CD.30,38,39,40 There is also the possibility that
changes in ALP were secondary to other causes like low vitamin D
status. Unfortunately, vitamin D levels were not assessed in this
study but it is felt the likelihood of this altering the results signifi-
cantly is low as all patients were treated at large academic centres
where Vitamin D levels are routinely assessed and aggressively
replaced. Finally, this study is limited by its short duration of follow-
up. Changes in liver biochemistries were only assessed to week 30
of therapy and, therefore, longer term outcomes such as need for
liver transplantation, development of cirrhosis or cancer incidence
were unable to be assessed. Clearly larger, prospective, multi-centre
studies are required to look at this question in more detail.
In conclusion, our study did not demonstrate sustained improve-
ment in liver biochemistries in patients with UC and PSC treated
with vedolizumab, and in fact revealed a modest increase in alkaline
phosphatase in patients who had normal levels prior to vedolizumab
commencement. This increase rarely resulted in discontinuation of
vedolizumab, and we have demonstrated that vedolizumab therapy
appears safe in patients with PSC, advanced liver disease and a his-
tory of orthotopic liver transplantation. In addition, clinical response
and remission in IBD activity seems to be similar to the population
of patients with IBD without PSC, although rates of mucosal healing
may be lower. Future registry studies should focus more on whether
vedolizumab can improve long-term clinical outcomes in PSC
patients including decreasing the development of new biliary stric-
tures, cirrhosis, need for transplantation and cancer incidence.
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